Serum and peritoneal exudate concentrations after high doses of β-lactams in critically ill patients with severe intra-abdominal infections: an observational prospective study
Authors:
- 10 October 2019
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 75 (1) , 156-161
Abstract
Background: Critically ill patients with severe intra-abdominal infections (IAIs) requiring surgery may undergo several pharmacokinetic (PK) alterations that can lead to β-lactam underdosage. Objectives: To measure serum and peritoneal exudate concentrations of β-lactams after high doses and optimal administration schemes. Methods: This observational prospective study included critically ill patients with suspicion of IAI who required surgery and a β-lactam antibiotic as empirical therapy. Serum and peritoneal exudate concentrations were measured during surgery and after a 24 h steady-state period. The PK/pharmacodynamic (PD) target was to obtain serum β-lactam concentrations of 100% fT>4×MIC based on a worst-case scenario (based on the EUCAST highest epidemiological cut-off values) before bacterial documentation (a priori) and redefined following determination of the MIC for the isolated bacteria (a posteriori). Registered with ClinicalTrials.gov (NCT03310606). Results: Forty-eight patients were included with a median (IQR) age of 64 (53–74) years and a SAPS II of 40 (32–65). The main diagnosis was secondary nosocomial peritonitis. Piperacillin/tazobactam was the most administered β-lactam antibiotic (75%). The serum/peritoneal piperacillin/tazobactam ratio was 0.88 (0.64–0.97) after a 24 h steady-state period. Prior to bacterial documentation, 16 patients (33.3%) achieved the a priori PK/PD target. The identification of microorganisms was available for 34 patients (71%). Based on the MIC for isolated bacteria, 78% of the patients achieved the serum PK/PD target. Conclusions: In severe IAIs, high doses of β-lactams ensured 100% fT>4×MIC in the serum for 78% of critically ill patients with severe IAIs within the first 24 h. In order to define optimal β-lactam dosing, the PK/PD target should take into account the tissue penetration and local ecology.Keywords
Funding Information
- Department of Anaesthesiology and Intensive Care Medicine
- University Hospital of Nancy
This publication has 16 references indexed in Scilit:
- Optimization of the treatment with beta-lactam antibiotics in critically ill patients—guidelines from the French Society of Pharmacology and Therapeutics (Société Française de Pharmacologie et Thérapeutique—SFPT) and the French Society of Anaesthesia and Intensive Care Medicine (Société Française d’Anesthésie et Réanimation—SFAR)Critical Care, 2019
- Population pharmacokinetics of continuous infusion of piperacillin in critically ill patientsInternational Journal of Antimicrobial Agents, 2018
- Erratum to: Antimicrobials: a global alliance for optimizing their rational use in intra-abdominal infections (AGORA)World Journal of Emergency Surgery, 2017
- The degree of local inflammatory response after colonic resection depends on the surgical approach: an observational study in 61 patientsBMC Surgery, 2015
- Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutionsThe Lancet Infectious Diseases, 2014
- Pharmacokinetics of meropenem and piperacillin in critically ill patients with indwelling surgical drainsInternational Journal of Antimicrobial Agents, 2013
- Pharmacokinetics of Beta-Lactam Antibiotics in Patients with Intra-Abdominal Disease: A Structured ReviewSurgical Infections, 2012
- Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shockCritical Care, 2010
- Plasma and peritoneal concentration following continuous infusion of cefotaxime in patients with secondary peritonitisJournal of Antimicrobial Chemotherapy, 2009
- Pharmacokinetics of ceftazidime in serum and peritoneal exudate during continuous versus intermittent administration to patients with severe intra-abdominal infectionsJournal of Antimicrobial Chemotherapy, 2002